toceranib-phosphate and Thrombocytopenia

toceranib-phosphate has been researched along with Thrombocytopenia* in 1 studies

Other Studies

1 other study(ies) available for toceranib-phosphate and Thrombocytopenia

Article	Year
Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats. Veterinary and comparative oncology, 2017, Volume: 15, Issue:3 The purpose of this study was to describe the toxicity profile of toceranib phosphate in tumour bearing cats. Medical records were reviewed from seven institutions. Patients with incomplete medical records and those receiving concurrent chemotherapy or NSAIDs (non-steroidal anti-inflammatory) were excluded. Fifty-five cats met the inclusion criteria. Carcinoma was diagnosed in 55% of cases. Median oral toceranib dose was 2.7 mg kg Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Azotemia; Cat Diseases; Cats; Female; Gastrointestinal Tract; Indoles; Male; Neoplasms; Neutropenia; Pyrroles; Retrospective Studies; Thrombocytopenia	2017

Article

Year

Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.

Veterinary and comparative oncology, 2017, Volume: 15, Issue:3

The purpose of this study was to describe the toxicity profile of toceranib phosphate in tumour bearing cats. Medical records were reviewed from seven institutions. Patients with incomplete medical records and those receiving concurrent chemotherapy or NSAIDs (non-steroidal anti-inflammatory) were excluded. Fifty-five cats met the inclusion criteria. Carcinoma was diagnosed in 55% of cases. Median oral toceranib dose was 2.7 mg kg

Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Azotemia; Cat Diseases; Cats; Female; Gastrointestinal Tract; Indoles; Male; Neoplasms; Neutropenia; Pyrroles; Retrospective Studies; Thrombocytopenia

2017